Skip to content
Search

Latest Stories

18 drugs in October price concessions list

Pb Staff writer
By Pb Staff writerOct 15, 2020
Pb Staff writer
See Full Bio

The Department of Health and Social Care (DH) on Thursday (October 15) released first price concessions list for October 2020. The list of 18 drugs includes...

DrugPack SizePrice Concession
Duloxetine 20mg gastro-resistant capsules28£7.99
Duloxetine 60mg gastro-resistant capsules28£4.10
Enalapril 10mg tablets28£5.49
Enalapril 20mg tablets28£10.00
Estradiol 1mg tablets84£6.89
Estradiol 2mg tablets84£6.89
Hydroxyzine 10mg tablets84£1.77
Moxonidine 200microgram tablets28£9.46
Moxonidine 300microgram tablets28£10.99
Moxonidine 400microgram tablets28£12.07
Naftidrofuryl 100mg capsules84£7.25
Olanzapine 15mg tablets28£3.95
Olanzapine 20mg tablets28£5.10
Oxytetracycline 250mg tablets28£9.10
Senna 7.5mg tablets60£2.76
Sertraline 100mg tablets28£6.72
Sertraline 50mg tablets28£4.74
Valsartan 160mg capsules28£12.01

Related News

GP surgery upgrades for annual appointments
News

GP surgery upgrades to create 8.3 million more annual appointments

Empowering women in pharmacy through self-advocacy
Guest Blog

Advocate for yourself – Celebrating International Women’s Day

NHS England Abolition: Wes Streeting outlines progress
News

Wes Streeting provides update on NHS England Abolition

It is official: Opella is now a standalone company
News

Opella becomes standalone company as Sanofi-CD&R deal closes

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Pharmacist declining participation in assisted dying under new UK legislation

It could take another four years for assisted dying to become law

Pic credit: iStock

Pharmacists to have choice to opt-out of assisted dying process

Pharmacists will not be forced to be a part in assisted dying cases with the MP leading the campaign expected to made amendments to the bill which is currently going through parliamentary process.

Kim Leadbeater, the MP behind the Terminally Ill Adults (End of Life) Bill, will say that “no person is under any duty to participate in the provision of assistance”.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc